Medivir AB has entered into a license agreement with Ferrer for exclusive rights to commercialize Adasuve inhaled loxapine in Denmark, Finland, Norway, Iceland and Sweden. The company is paying Ferrer an undisclosed amount up front, plus sales-based milestone payments.
Medivir CEO Maris Hartmanis commented, “This licensing agreement is in line with our strategy to add new products to our Nordic portfolio. Adasuve is the first addition to the portfolio, which now consists of 16 prescription pharmaceuticals. Adasuve is a very interesting product based on a novel administration technology addressing an unmet medical need, which expands our present offering to psychiatrists, Lithionit. We are excited about having secured the commercial rights to Adasuve for the Nordic region and the partnership with Ferrer”.
Ferrer COO Antoni Villaró added, “We believe that Adasuve will be a breakthrough in the treatment of agitation and is going to change the way in which the condition is viewed by both healthcare professionals and patients. We are excited to be introducing Adasuve to the European psychiatric and hospital treatment community as Adasuve is now available in Germany, and thank to this agreement soon in the Nordic countries.”
Adasuve loxapine inhalation powder was developed by Alexza for the treatment of agitation in schizophrenia patients. Ferrer acquired the rights to commercialize Adasuve in Europe, Commonwealth of Independent States countries, and Latin America in 2011. Teva obtained US rights to Adasuve in May 2013.
Read the Medivir press release.
